{"id":3661,"date":"2023-03-03T17:32:28","date_gmt":"2023-03-03T16:32:28","guid":{"rendered":"https:\/\/www.access2meds.eu\/konzorcij\/"},"modified":"2025-06-24T10:06:18","modified_gmt":"2025-06-24T08:06:18","slug":"konzorcij","status":"publish","type":"page","link":"https:\/\/www.access2meds.eu\/hr\/konzorcij\/","title":{"rendered":"Konzorcij"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.27.4″ _module_preset=”2e264158-b54d-4d7f-8146-8c8b7ca64cef” background_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1200929353_SolStock-e1679656039802.jpg” background_position=”top_center” background_last_edited=”on|phone” background_image_phone=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/06\/Mobile-Header-2.png” background_enable_image_phone=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.0″ _module_preset=”default” custom_padding=”7px|30px||30px|false|true” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” header_font=”|700||on|||||” header_text_color=”#E85D6B” header_font_size=”60px” custom_margin=”11px||||false|false” global_colors_info=”{}”]<\/p>\n

Konzorcij<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”first text colored pill” _builder_version=”4.20.0″ _module_preset=”default” background_enable_color=”off” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.2″ _module_preset=”default” vertical_offset=”-164px” custom_margin=”||-153px||false|false” custom_padding=”|0px||0px|false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_text_color=”#FFFFFF” text_font_size=”20px” text_line_height=”1.33em” header_2_font=”Poppins regular||||||||” header_2_text_color=”#FFFFFF” header_2_font_size=”24px” background_color=”#048EA3″ max_width=”635px” module_alignment=”left” custom_padding=”60px|92px|60px|30px|true|false” custom_css_main_element=”overflow:visible;” custom_css_after=”content:%22%22; display:block; width:2000px; height:100%; background:#048ea3; position:absolute; top:0;right:635px;” border_radii=”off||999px|999px|” global_colors_info=”{}”]<\/p>\n

Ovaj odjeljak pru\u017ea pregled konzorcija projekta ASCERTAIN, uklju\u010duju\u0107i informacije o projektnim partnerima i njihovim ulogama i odgovornostima.<\/p>\n

Mi smo konzorcij partnera iz sedam zemalja (Austrije, Belgije, Nizozemske, Slova\u010dke, Norve\u0161ke, Njema\u010dke i Italije) koji sura\u0111uju.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” custom_padding=”8px||36px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” custom_padding=”|30px|40px|30px|false|true” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/logo-erasmus-universiteit.png” title_text=”logo-erasmus-universiteit” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-erasmus-universiteit-rotterdam\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Erasmus Universiteit Rotterdam<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Sveu\u010dili\u0161te Erasmus Rotterdam (EUR) je sveu\u010dili\u0161te u Rotterdamu u Nizozemskoj s 3700 akademskih djelatnika i 23 867 studenata. Erasmus \u0161kola za zdravstvenu politiku i menad\u017ement (ESHPM) je multidisciplinarna istra\u017eiva\u010dka i nastavna \u0161kola na sveu\u010dili\u0161tu. Jedan od njegovih odjela, Institut za procjenu medicinske tehnologije (iMTA), odigrao je klju\u010dnu ulogu u istra\u017eivanju zdravstvenih tehnologija u Nizozemskoj, Europi i svijetu. Institut je proveo vi\u0161e od 600 istra\u017eiva\u010dkih projekata u zdravstvu koje su sponzorirala velika financijska tijela poput vlada i vladinih institucija, Europske komisije, WHO-a, zdravstvenih organizacija, dobrotvornih zaklada i farmaceutske industrije. <\/p>\n

Uloga u projektu:<\/strong> EUR je koordinator ovog projekta i doprinosi projektu stru\u010dno\u0161\u0107u u podru\u010dju odre\u0111ivanja cijena, genske i stani\u010dne terapije te nadoknade tro\u0161kova.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-erasmus-universiteit-rotterdam\/” button_text=”Pogledajte tim!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”#fbedec” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}” custom_css_main_element_tablet=”width:20.65% !important;”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Comenius_University_Bratislava.svg” title_text=”Comenius_Sveu\u010dili\u0161te_Bratislava” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-comenius-university-bratislava\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_padding_phone=”|0px|20px||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}” custom_css_main_element_tablet=”width:79.35% !important;”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”0px||22px||false|false” global_colors_info=”{}”]<\/p>\n

Sveu\u010dili\u0161te Comenius u Bratislavi (UNIBA)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Sveu\u010dili\u0161te Comenius u Bratislavi istra\u017eiva\u010dka je institucija koja provodi stotine doma\u0107ih i me\u0111unarodnih istra\u017eiva\u010dkih projekata. Predstavnik Farmaceutskog fakulteta Sveu\u010dili\u0161ta Comenius u Bratislavi bio je \u010dlan Odbora za naknadu tro\u0161kova za lijekove slova\u010dkog Ministarstva zdravstva u ime Saveznog fonda zdravstvenog osiguranja. <\/p>\n

Uloga u projektu: <\/strong>UNIBA pru\u017ea stru\u010dnost u podru\u010dju medicinskih proizvoda i modela naknada tro\u0161kova.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-comenius-university-bratislava\/” button_text=”Pogledajte tim!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ locked=”off” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”#FFFFFF” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/06\/wortbildmarke-goeg-RGB.png” title_text=”oznaka-wortbild-goeg-RGB” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-gesundheit-osterreich-gmbh\/” _builder_version=”4.25.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=”200px” custom_margin=”5px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Gesundheit \u00d6sterreich GmbH (GOEG)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Austrijski nacionalni institut za javno zdravstvo (Gesundheit \u00d6sterreich GmbH) je institucija odgovorna za istra\u017eivanje i planiranje javnog zdravstva u Austriji. Tako\u0111er djeluje kao nacionalni centar za kompetencije i financiranje promicanja i prevencije zdravlja te olak\u0161ava istra\u017eivanja vezana uz zdravstvo. GOEG je javno, neprofitno dru\u0161tvo s ograni\u010denom odgovorno\u0161\u0107u u potpunom vlasni\u0161tvu Republike Austrije, koju zastupa Savezno ministarstvo socijalnih poslova, zdravstva, skrbi i za\u0161tite potro\u0161a\u010da. <\/p>\n

Uloga u projektu:<\/strong> GOEG pru\u017ea stru\u010dnost u podru\u010dju odre\u0111ivanja cijena lijekova, politika odre\u0111ivanja cijena i naknada za farmaceutske proizvode i medicinske proizvode te u komparativnim istra\u017eivanjima farmaceutskih sustava. Zahvaljuju\u0107i suradnji s kreatorima politika, GOEG tako\u0111er doprinosi razmjeni informacija i suradnji me\u0111u zemljama u projektu. <\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-gesundheit-osterreich-gmbh\/” button_text=”Pogledajte tim!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”rgba(57,60,132,0.15)” custom_padding=”45px||45px||true|false” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/university-of-oslo.png” title_text=”sveu\u010dili\u0161te u Oslu” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-universitetet-i-oslo\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_margin=”5px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Universitetet i Oslo <\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Sveu\u010dili\u0161te u Oslu najve\u0107e je i najstarije sveu\u010dili\u0161te u Norve\u0161koj. Sveu\u010dili\u0161te ima 27 700 studenata i 6 000 zaposlenika. Sveu\u010dili\u0161te se sastoji od pet fakulteta koji provode istra\u017eivanja i pru\u017eaju nastavu iz teologije, prava, medicine, humanisti\u010dkih znanosti, matematike i prirodnih znanosti, stomatologije i dru\u0161tvenih znanosti. Temeljne aktivnosti Medicinskog fakulteta su istra\u017eivanje, obrazovanje, diseminacija i inovacije za dobrobit pacijenata i dru\u0161tva. <\/p>\n

Uloga u projektu: <\/strong>UIO doprinosi u slu\u010dajevima upotrebe preciznih lijekova i medicinskih proizvoda za rak, te stru\u010dno\u0161\u0107u u HTA-i, matemati\u010dkim simulacijskim modelima, postavljanju prioriteta i analizi podataka registara.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-universitetet-i-oslo\/” button_text=”Pogledajte tim!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”#FFFFFF” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/AIM-LOGO_png24.png” title_text=”AIM-LOGO_png24″ url=”https:\/\/www.access2meds.eu\/consortium\/team-members-association-internationale-de-la-mutualite-aim\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=”150px” custom_margin=”5px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Association Internationale de la Mutualit\u00e9 (AIM)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

AIM je krovna organizacija federacija zdravstvenih uzajamnih tijela i tijela zdravstvenog osiguranja sa \u0161irokom europskom bazom od 30 \u010dlanova u 18 zemalja, koja pokriva 200 milijuna europskih gra\u0111ana.
Ova organizacija platitelja oslanja se na opse\u017enu stru\u010dnost medicinskog i zdravstvenog ekonomskog osoblja iz svih europskih regija.
AIM je 2019. predstavio inovativni model za pravednu europsku cijenu za inovativne lijekove. Godine 2021. kalkulator, prakti\u010dan alat za kori\u0161tenje modela, postao je dostupan na njezinoj web stranici.<\/p>\n

Uloga u projektu:<\/strong> Inovativni algoritam koji kombinira priu\u0161tivost i podr\u0161ku vrijednim inovacijama bit \u0107e osnova za inovativni model odre\u0111ivanja cijena u ASCERTAIN-u.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-association-internationale-de-la-mutualite-aim\/” button_text=”Pogledajte tim!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”rgba(133,184,189,0.3)” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/08\/Logo-EHA-Black.png” title_text=”Logo EHA – Crni” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-european-hematology-association\/” _builder_version=”4.27.0″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=”150px” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

European Hematology Association (EHA) <\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Europsko hematolo\u0161ko udru\u017eenje (EHA) \u2013 EHA je nevladina i neprofitna organizacija \u010dlanova vo\u0111ena misijom promicanja izvrsnosti u skrbi za pacijente, istra\u017eivanju i obrazovanju u hematologiji. EHA je najve\u0107a europska organizacija koja okuplja medicinske stru\u010dnjake, istra\u017eiva\u010de i znanstvenike zainteresirane za hematologiju. EHA predstavlja hematologiju i hematologe na europskoj politi\u010dkoj sceni I zdravstvenim politikama s ciljem pobolj\u0161anja regulacije, pove\u0107anja dostupnosti i priu\u0161tivosti lijekova te uskla\u0111ivanja obrazovanja i osposobljavanja hematologa. <\/p>\n

Uloga u projektu: <\/strong>doprinosi stru\u010dno\u0161\u0107u u odre\u0111ivanju cijena i tro\u0161kovne u\u010dinkovitosti.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-european-hematology-association\/” button_text=”Pogledajte tim!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”#FFFFFF” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Chino.io-logo.png” title_text=”Chino.io – logotip” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-chino-srl\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Chino.io (CHINO)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Chino SRL je talijanska tvrtka za kiberneti\u010dku sigurnost i tehnologiju u oblaku osnovana 2014. godine s misijom pomaganja programerima zdravstvenih aplikacija u rje\u0161avanju problema uskla\u0111enosti sa sigurnosnim i privatnostnim zakonima pri radu s osjetljivim zdravstveno-osjetljivim podacima u oblaku. Chino SRL je stvorio platformu za razvoj softvera pod nazivom Chino.io. Platforma nudi programerima skup API-ja za sigurno pohranjivanje, dijeljenje i upravljanje osjetljivim zdravstvenim podacima te potpuno uskla\u0111ivanje sa svim zakonima o za\u0161titi podataka, uklju\u010duju\u0107i GDPR, ePrivacy i HIPAA. <\/p>\n

Uloga u projektu:<\/strong><\/span><\/strong> Upravljanje podacima i etika u WP2.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-chino-srl\/” button_text=”Pogledajte tim!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.0″ _module_preset=”default” background_color=”#fbedec” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/MPE-Logo.png” title_text=”Logotip MPE-a” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-myeloma-patients-europe-aisbl\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=”100px” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

Myeloma Patients Europe (MPE)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Myeloma Patients Europe (MPE) je krovna organizacija udruga pacijenata s mijelomom i AL amiloidozom diljem Europe. MPE trenutno ima 53 \u010dlana sa sjedi\u0161tem u 33 zemlje. Misija organizacije je pru\u017eanje edukacije, informacija i podr\u0161ke udrugama \u010dlanicama te zagovaranje na europskoj, nacionalnoj i lokalnoj razini za najbolja mogu\u0107a istra\u017eivanja i jednak pristup lije\u010denju i skrbi. Kako bi postigla svoje ciljeve, MPE izravno sura\u0111uje s \u010dlanovima, zdravstvenim djelatnicima, tijelima za nadoknadu tro\u0161kova, regulatorima, politi\u010darima, farmaceutskim tvrtkama i medijima kako bi osigurala suradnju svih dionika na pobolj\u0161anju ishoda pacijenata i smanjenju nejednakosti diljem Europe. <\/p>\n

Uloga u projektu:<\/strong> anga\u017eman pacijenata, identificiranje potreba i preferencija pacijenata za razvoj modela.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-myeloma-patients-europe-aisbl\/” button_text=”Pogledajte tim!” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”RGBA(255,255,255,0)” custom_padding=”45px||45px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=”|25px|||false|false” custom_css_main_element=”width:20.65% !important;” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/OptiMedis_RGB.svg” title_text=”OptiMedis_RGB” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-optimedis-ag\/” _builder_version=”4.20.2″ _module_preset=”26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=”130px” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.20.2″ _module_preset=”f72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” text_text_color=”#393C84″ header_2_font=”Poppins semibold|||on|||||” header_2_line_height=”1.1em” custom_margin=”||22px||false|false” global_colors_info=”{}”]<\/p>\n

OptiMedis AG (OM)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

OptiMedis je tvrtka za upravljanje i analizu zdravstvenih podataka registrirana u Njema\u010dkoj. Njezina osnovna djelatnost je razvoj i upravljanje regionalnim integriranim sustavima pru\u017eanja zdravstvene skrbi s lije\u010dni\u010dkim mre\u017eama i drugim pru\u017eateljima usluga. OptiMedis-ov pristup transformaciji zdravstvenih sustava \u010desto je prepoznat od strane EU, vi\u0161e istra\u017eiva\u010dkih projekata EU, Commonwealth fonda, Centra za zdravstvenu politiku Duke Margolis, WHO-a, Svjetske banke i drugih. OptiMedis upravlja s tri integrirana sustava pru\u017eanja zdravstvene skrbi u Njema\u010dkoj s populacijom ve\u0107om od 120 000 stanovnika i u koju je uklju\u010deno vi\u0161e od 150 pru\u017eatelja zdravstvene skrbi. OptiMedis je trenutno uklju\u010den u konkurentne istra\u017eiva\u010dke i implementacijske projekte s vrijednosti ve\u0107om od 10 milijuna eura. <\/p>\n

Uloga u projektu:<\/strong> Aktivnosti \u0161irenja i iskori\u0161tavanja projekta, zelena proizvodnja zdravstvene tehnologije.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/consortium\/team-members-optimedis-ag\/” button_text=”Pogledajte tim!” button_alignment=”left” _builder_version=”4.20.2″ _module_preset=”934a713e-7600-4210-b519-38aa562ec140″ button_bg_color=”RGBA(255,255,255,0)” custom_padding_last_edited=”off|phone” button_font_last_edited=”off|desktop” global_colors_info=”{}” button_bg_enable_color__hover=”on”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”kontakt” _builder_version=”4.20.2″ _module_preset=”default” background_color=”#86B8BD” custom_margin=”||||false|false” custom_padding=”16px||75px||false|false” box_shadow_style=”preset7″ box_shadow_horizontal=”0px” box_shadow_vertical=”-274px” box_shadow_color=”#FFFFFF” global_module=”910″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” header_font=”Poppins semibold|||on|||||” header_font_size=”36px” custom_margin=”14px||23px||false|false” custom_margin_tablet=”” custom_margin_phone=”||30px||false|false” custom_margin_last_edited=”on|phone” header_font_size_phone=”24px” global_colors_info=”{}”]<\/p>\n

Kontakt<\/h1>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_font=”Poppins regular||||||||” text_text_color=”#393C84″ text_font_size=”24px” text_line_height=”1.33em” module_alignment=”right” custom_margin=”||0px||false|false” text_font_size_tablet=”” text_font_size_phone=”18px” text_font_size_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

Molimo kontaktirajte nas ako imate bilo kakvih pitanja ili komentara! Odgovorit \u0107emo vam u najkra\u0107em mogu\u0107em roku. <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” module_class=”tablet-three-cols” _builder_version=”4.20.2″ _module_preset=”default” max_width_tablet=”980px” max_width_phone=”500px” max_width_last_edited=”on|phone” custom_padding=”0px|30px|0px|30px|false|true” global_colors_info=”{}” custom_css_main_element_last_edited=”on|phone” custom_css_main_element_tablet=”display:flex;” custom_css_main_element_phone=”display:flex; flex-direction:column;”][et_pb_column type=”1_3″ _builder_version=”4.20.2″ _module_preset=”be0fba28-f74a-4ba0-9a8d-9cd30aca805d” global_colors_info=”{}” custom_css_main_element_last_edited=”on|tablet” custom_css_main_element_tablet=”margin-bottom:0;” custom_css_main_element_phone=”margin-bottom:20px;”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Carin_Uyl-de-Groot.png” title_text=”Carin_Uyl-de-Groot” _builder_version=”4.20.2″ _module_preset=”a348f9e0-d57b-4c22-b522-c52b784fe57f” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_text_color=”#FFFFFF” link_text_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n

Za pitanja vezana uz istra\u017eivanje:<\/p>\n

Carin Uyl-de Groot<\/strong>
Koordinator projekta<\/p>\n

Sveu\u010dili\u0161te Erasmus u Rotterdamu
uyl@eshpm.eur.nl<\/a>
Telefon: +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.20.2″ _module_preset=”be0fba28-f74a-4ba0-9a8d-9cd30aca805d” background_color=”#393C84″ global_colors_info=”{}” custom_css_main_element_last_edited=”on|phone” custom_css_main_element_tablet=”margin-bottom:0;” custom_css_main_element_phone=”margin-bottom:20px;”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Marcel-Langone-1.png” title_text=”Marcel-Langone” align=”center” _builder_version=”4.20.2″ _module_preset=”a348f9e0-d57b-4c22-b522-c52b784fe57f” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_text_color=”#FFFFFF” link_text_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n

Za op\u0107a pitanja o projektu:<\/p>\n

Marcel Langone Marques<\/strong>
Voditelj projekta<\/p>\n

Sveu\u010dili\u0161te Erasmus u Rotterdamu
marcel.langonemarques@eur.nl<\/a>
Telefon: +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.20.2″ _module_preset=”be0fba28-f74a-4ba0-9a8d-9cd30aca805d” background_color=”#048EA3″ global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/06\/My-project-1-7.png” title_text=”Moj projekt-1 (7)” _builder_version=”4.21.0″ _module_preset=”a348f9e0-d57b-4c22-b522-c52b784fe57f” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_text_color=”#FFFFFF” link_text_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n

Za komunikacije:<\/p>\n

Lena Jessen<\/strong>
Voditelj projekta<\/p>\n

OptiMedis
l.jessen@optimedis.de<\/a>
Telefon: +49 40 226211490<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

KonzorcijOvaj odjeljak pru\u017ea pregled konzorcija projekta ASCERTAIN, uklju\u010duju\u0107i informacije o projektnim partnerima i njihovim ulogama i odgovornostima. Mi smo konzorcij partnera iz sedam zemalja (Austrije, Belgije, Nizozemske, Slova\u010dke, Norve\u0161ke, Njema\u010dke i Italije) koji sura\u0111uju.Erasmus Universiteit RotterdamSveu\u010dili\u0161te Erasmus Rotterdam (EUR) je sveu\u010dili\u0161te u Rotterdamu u Nizozemskoj s 3700 akademskih djelatnika i 23 867 studenata. Erasmus \u0161kola za zdravstvenu politiku i menad\u017ement (ESHPM) je multidisciplinarna istra\u017eiva\u010dka i nastavna \u0161kola na sveu\u010dili\u0161tu. Jedan od njegovih odjela, Institut za procjenu medicinske tehnologije (iMTA), odigrao je klju\u010dnu ulogu u istra\u017eivanju zdravstvenih tehnologija u Nizozemskoj, Europi i svijetu. Institut je proveo vi\u0161e od 600 istra\u017eiva\u010dkih projekata u zdravstvu koje su sponzorirala velika financijska tijela poput vlada i vladinih institucija, Europske komisije, WHO-a, zdravstvenih organizacija, dobrotvornih zaklada i farmaceutske industrije. Uloga u projektu: EUR je koordinator ovog projekta i doprinosi projektu stru\u010dno\u0161\u0107u u podru\u010dju odre\u0111ivanja cijena, genske i stani\u010dne terapije te nadoknade tro\u0161kova.Sveu\u010dili\u0161te Comenius u Bratislavi (UNIBA)Sveu\u010dili\u0161te Comenius u Bratislavi istra\u017eiva\u010dka je institucija koja provodi stotine doma\u0107ih i me\u0111unarodnih istra\u017eiva\u010dkih projekata. Predstavnik Farmaceutskog fakulteta Sveu\u010dili\u0161ta Comenius u Bratislavi bio je \u010dlan Odbora za naknadu tro\u0161kova za lijekove slova\u010dkog Ministarstva zdravstva u ime Saveznog fonda zdravstvenog osiguranja. Uloga u projektu: UNIBA pru\u017ea stru\u010dnost u podru\u010dju medicinskih proizvoda i […]<\/p>\n","protected":false},"author":1,"featured_media":2552,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-3661","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nKonzorcij - ASCERTAIN<\/title>\n<meta name=\"description\" content=\"Projekt ASCERTAIN okuplja deset partnera iz sedam zemalja \u2013 Austrije, Belgije, Nizozemske, Slova\u010dke, Norve\u0161ke, Njema\u010dke i Italije.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.access2meds.eu\/hr\/konzorcij\/\" \/>\n<meta property=\"og:locale\" content=\"hr_HR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Konzorcij\" \/>\n<meta property=\"og:description\" content=\"Projekt ASCERTAIN okuplja deset partnera iz sedam zemalja \u2013 Austrije, Belgije, Nizozemske, Slova\u010dke, Norve\u0161ke, Njema\u010dke i Italije.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.access2meds.eu\/hr\/konzorcij\/\" \/>\n<meta property=\"og:site_name\" content=\"ASCERTAIN\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T08:06:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1254\" \/>\n\t<meta property=\"og:image:height\" content=\"836\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:label1\" content=\"Procijenjeno vrijeme \u010ditanja\" \/>\n\t<meta name=\"twitter:data1\" content=\"21 minuta\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/hr\\\/konzorcij\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/hr\\\/konzorcij\\\/\",\"name\":\"Konzorcij - ASCERTAIN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/hr\\\/konzorcij\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/hr\\\/konzorcij\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"datePublished\":\"2023-03-03T16:32:28+00:00\",\"dateModified\":\"2025-06-24T08:06:18+00:00\",\"description\":\"Projekt ASCERTAIN okuplja deset partnera iz sedam zemalja \u2013 Austrije, Belgije, Nizozemske, Slova\u010dke, Norve\u0161ke, Njema\u010dke i Italije.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/hr\\\/konzorcij\\\/#breadcrumb\"},\"inLanguage\":\"hr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.access2meds.eu\\\/hr\\\/konzorcij\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"hr\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/hr\\\/konzorcij\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"width\":1254,\"height\":836},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/hr\\\/konzorcij\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.access2meds.eu\\\/hr\\\/pocetna-stranica\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Konzorcij\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"name\":\"ASCERTAIN\",\"description\":\"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.access2meds.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"hr\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\",\"name\":\"ASCERTAIN\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"hr\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"ASCERTAIN\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/ASCERTAIN_EU\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ascertain-eu\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@ascertainproject\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Konzorcij - ASCERTAIN","description":"Projekt ASCERTAIN okuplja deset partnera iz sedam zemalja \u2013 Austrije, Belgije, Nizozemske, Slova\u010dke, Norve\u0161ke, Njema\u010dke i Italije.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.access2meds.eu\/hr\/konzorcij\/","og_locale":"hr_HR","og_type":"article","og_title":"Konzorcij","og_description":"Projekt ASCERTAIN okuplja deset partnera iz sedam zemalja \u2013 Austrije, Belgije, Nizozemske, Slova\u010dke, Norve\u0161ke, Njema\u010dke i Italije.","og_url":"https:\/\/www.access2meds.eu\/hr\/konzorcij\/","og_site_name":"ASCERTAIN","article_modified_time":"2025-06-24T08:06:18+00:00","og_image":[{"width":1254,"height":836,"url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ASCERTAIN_EU","twitter_misc":{"Procijenjeno vrijeme \u010ditanja":"21 minuta"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.access2meds.eu\/hr\/konzorcij\/","url":"https:\/\/www.access2meds.eu\/hr\/konzorcij\/","name":"Konzorcij - ASCERTAIN","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.access2meds.eu\/hr\/konzorcij\/#primaryimage"},"image":{"@id":"https:\/\/www.access2meds.eu\/hr\/konzorcij\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","datePublished":"2023-03-03T16:32:28+00:00","dateModified":"2025-06-24T08:06:18+00:00","description":"Projekt ASCERTAIN okuplja deset partnera iz sedam zemalja \u2013 Austrije, Belgije, Nizozemske, Slova\u010dke, Norve\u0161ke, Njema\u010dke i Italije.","breadcrumb":{"@id":"https:\/\/www.access2meds.eu\/hr\/konzorcij\/#breadcrumb"},"inLanguage":"hr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.access2meds.eu\/hr\/konzorcij\/"]}]},{"@type":"ImageObject","inLanguage":"hr","@id":"https:\/\/www.access2meds.eu\/hr\/konzorcij\/#primaryimage","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","width":1254,"height":836},{"@type":"BreadcrumbList","@id":"https:\/\/www.access2meds.eu\/hr\/konzorcij\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.access2meds.eu\/hr\/pocetna-stranica\/"},{"@type":"ListItem","position":2,"name":"Konzorcij"}]},{"@type":"WebSite","@id":"https:\/\/www.access2meds.eu\/#website","url":"https:\/\/www.access2meds.eu\/","name":"ASCERTAIN","description":"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES","publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.access2meds.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"hr"},{"@type":"Organization","@id":"https:\/\/www.access2meds.eu\/#organization","name":"ASCERTAIN","url":"https:\/\/www.access2meds.eu\/","logo":{"@type":"ImageObject","inLanguage":"hr","@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","width":1,"height":1,"caption":"ASCERTAIN"},"image":{"@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ASCERTAIN_EU","https:\/\/www.linkedin.com\/company\/ascertain-eu\/","https:\/\/www.youtube.com\/@ascertainproject"]}]}},"_links":{"self":[{"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/pages\/3661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/comments?post=3661"}],"version-history":[{"count":9,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/pages\/3661\/revisions"}],"predecessor-version":[{"id":4511,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/pages\/3661\/revisions\/4511"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/media\/2552"}],"wp:attachment":[{"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/media?parent=3661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}